Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs MRG-110 (Primary)
- Indications Heart failure; Ischaemia
- Focus Adverse reactions; First in man
- Sponsors Servier
- 16 Oct 2019 According to a miRagen Therapeutics media release, data of this trial will be included in an oral presentation detailing the MRG-110 program provided by Dr. Rusty L. Montgomery, Director of Research, miRagen Therapeutics, today at the 15th annual meeting of the Oligonucleotide Therapeutics Society, which is being held in Munich, Germany. The presentation will be available on the scientific publications page of the Companys website following the presentation.
- 16 Oct 2019 Results presented in a miRagen Therapeutics Media Release.
- 25 Apr 2019 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History